Navigation Links
Results of the OPTIMIZE trial presented at TCT 2013
Date:10/31/2013

SAN FRANCISCO, CA OCTOBER 31, 2013 - A new study demonstrates that some patients may not need to receive prolonged anti-clotting therapy after drug-eluting stent (DES) implantation with the Endeavor zotarolimus-eluting stent, and that shortening the duration could reduce bleeding risks and treatment costs. The OPTIMIZE clinical trial findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Current guidelines recommend long-term (12 month) dual antiplatelet therapy (DAPT) after DES implantation, but the clinical benefits of this regimen remain unclear, especially with newer generation DES. The OPTIMIZE trial enrolled 3,120 patients with largely stable coronary artery disease in a prospective, randomized (1:1) multicenter clinical evaluation that compared short-term (3 month) and long-term (12 month) dual antiplatelet therapy. All patients underwent PCI with Endeavor zotarolimus-eluting stents, a second-generation DES.

The primary endpoint was a composite of Net Adverse Clinical and Cerebral Events (NACCE), which included death from any cause, myocardial infarction, stroke or major bleeding at one year follow-up.

After one year, NACCE rates for patients receiving short-term DAPT were similar to those who received the longer, standard DAPT (6.1 percent vs. 5.9 percent respectively), establishing non-inferiority of the shorter-term therapy (non-inferiority p-value = 0.002).

After 90 days, both groups showed comparable rates of NACCE, stent thrombosis and revascularization. Patients in the long-term DAPT group also showed a trend towards increased bleeding events.

"To date, OPTIMIZE is the only DAPT duration study using a single second-generation DES, and these promising findings could help shorten antiplatelet therapy time and reduce related complication risks for patients receiving select drug-eluting stents," said lead investigator Fausto Feres, MD of the Instituto Dante Pazzanese de Cardiologia in So Paulo, Brazil.

"These outcomes may be especially relevant for patients who are at a high risk of bleeding complications following PCI, such as the elderly and patients with a history of hemorrhagic events."


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. False-Positive Mammogram Results May Turn Out Not to Be: Study
2. Good intentions bring mixed results for Haitis disabled people
3. Presentation of 1-year IVAN and 2-year CATT study results
4. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
5. Surprising results for use of dialysis for kidney failure in developing world
6. Stem Cell Study Shows Promising Results Against Heart Failure
7. Automated insulin dosage titration system demonstrates positive clinical study results
8. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
9. Tight Blood-Sugar Control Shows Mixed Results for Health of Kidneys: Study
10. ACP-New York State Chapter partnership results in patient safety organization recognition
11. Long-term testosterone treatment for men results in reduced weight and waist size
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Roderick ... planning services to families and business owners in northern Florida, is joining the ... provide support to area adults with developmental challenges. , The First Coast YMCA ...
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed in the second ... of hospital acquisitions rose to 23 in the second quarter, up 15% from the ... the 20 announced deals in the year-ago second quarter. Only four of the transactions ...
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has launched ... of acceptance to a residency in a United States hospital. Being accepted into ... U.S. , According to data released by the ECFMG®, every year, 50 percent ...
(Date:7/21/2017)... ... July 21, 2017 , ... The most common surgical techniques ... of life five years after injury, according to research presented today at the ... Canada. The study followed patients for five years following surgery. , “Orthopaedic surgeons ...
(Date:7/20/2017)... July 20, 2017 (PRWEB) , ... ... ... Technologies, a global provider of enterprise-grade IT operations analytics and application performance ... of one of world’s largest healthcare services providers. , According to Peter ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017  US medical equipment and ... 2021, according to Medical Equipment & Supplies: ... Freedonia Focus Reports. Continued increases in demand for medical ... of the population and supported by gains in disposable ... and supplies. New product introductions will also drive sales ...
(Date:7/10/2017)... -- The tenth annual BioPharm America™ will take ... the Sheraton Boston Hotel, September 26–27. The event will ... makers and innovative biotech startup companies. The event is ... impactful days. BioPharm America is now part of Biotech ... with 4,500+ life science industry influencers participating in 8+ ...
(Date:7/5/2017)... 2017 Wolfmet 3D  printed tungsten collimator manufactured by M&I ... manufacturing combine to progress molecular radiotherapy imaging. In ... unable to accurately quantify the radiation absorbed by those patients ... success of this radiotherapy treatment has been available — that ... ...
Breaking Medicine Technology: